GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. Thes...

Pharmaceutical companies Bristol Myers Squibb and Sanofi have agreed to pay Hawaii USD 700 million to settle a lawsuit concerning the blood...

Drug major Cipla's subsidiary is voluntarily recalling one lot of medication in the US due to seal integrity issues. InvaGen Pharmaceutical...

Valiant Labs is an active pharmaceutical ingredient (API/bulk drug manufacturing company, with a focus on producing Paracetamol. APIs serve...

Considering the upper price band of Rs 140, the stock is likely to debut with a premium of 16%. The IPO was well-received by investors with...

Considering the upper price band of Rs 140, the stock is likely to debut with a premium of 16%. The IPO received a healthy subscription of ...

The offer, which is priced at Rs 133-140 apiece, is completely a fresh equity issue of 1.08 crore shares. Investors can bid for a minimum o...

The offer, which is priced at Rs 133-140 apiece, is completely a fresh equity issue of Rs 1.08 crore shares. Investors can bid for a minimu...

The company's IPO is completely a fresh equity issue of Rs 1.08 crore shares. About 50% of the offer is reserved for qualified institutiona...

The acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with ref...

Primcyv is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination wi...

The financial details of the acquisition were not disclosed. Following the acquisition, the two companies will be held by BSV.

The approval granted by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Paclitaxel injecti...

The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) fo...

Around 21 lakh people are estimated to be living with HIV in India but only 14 lakh are known cases, according to the health ministry.

The partnership will develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers.

A new agreement has been clinched with pharmaceutical firms to substantially decrease the cost of treating AIDS in 66 countries in Asia, La...